Gilead Sciences Inc (GILD): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2.4%. By the end of trading, Gilead rose $2.60 (3.2%) to $83.81 on average volume. Throughout the day, 14,677,600 shares of Gilead exchanged hands as compared to its average daily volume of 11,509,000 shares. The stock ranged in a price between $81.67-$83.98 after having opened the day at $81.92 as compared to the previous trading day's close of $81.21. Other companies within the Drugs industry that increased today were: Aoxing Pharmaceutical Company ( AXN), up 55.9%, Prana Biotechnology ( PRAN), up 39.3%, Forest Laboratories ( FRX), up 27.5% and Skystar Bio-Pharmaceutical Company ( SKBI), up 13.4%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $124.5 billion and is part of the health care sector. Shares are up 8.1% year to date as of the close of trading on Friday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, IntelliPharmaCeutics International ( IPCI), down 9.7%, iBio ( IBIO), down 6.0%, Alcobra ( ADHD), down 5.2% and La Jolla Pharmaceutical ( LJPC), down 5.1% , were all laggards within the drugs industry with Isis Pharmaceuticals ( ISIS) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start